These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 14934908)
1. [Mechanism of action of tromexan]. COSTANTINI A; TINTORI M Boll Soc Ital Biol Sper; 1951 Dec; 27(12):1652-5. PubMed ID: 14934908 [No Abstract] [Full Text] [Related]
2. A study on the toxicology and anticoagulant action of tromexan, a synthetic coumarin. GRUBER CM; LEE KS; LASZICZENKO T; GRUBER CM Arch Int Pharmacodyn Ther; 1951 Sep; 87(4):402-12. PubMed ID: 14895202 [No Abstract] [Full Text] [Related]
3. Clinical evaluation of ethyl biscoumacetate (tromexan). VANDER VEER JB; FUNK EH; BOYER FR; KELLER EA Am J Med; 1953 Jun; 14(6):694-703. PubMed ID: 13057879 [No Abstract] [Full Text] [Related]
4. The physiological disposition of ethyl biscoumacetate (tromexan) in man and a method for its estimation in biological material. BRODIE BB; WEINER M; BURNS JJ; SIMSON G; YALE EK J Pharmacol Exp Ther; 1952 Dec; 106(4):453-63. PubMed ID: 13023556 [No Abstract] [Full Text] [Related]
5. The biotransformation of ethyl biscoumacetate (tromexan) in man, rabbit and dog. BURNS JJ; WEINER M; SIMSON G; BRODIE BB J Pharmacol Exp Ther; 1953 May; 108(1):33-41. PubMed ID: 13053419 [No Abstract] [Full Text] [Related]
6. Ethyl biscoumacetate (tromexan) in coronary artery disease. POLLITZER RS J S C Med Assoc (Columbia); 1953 Mar; 49(3):66-8. PubMed ID: 13045283 [No Abstract] [Full Text] [Related]
7. Mode of action of tromexan. HUNTER RB; TUDHOPE GR Lancet; 1953 Apr; 1(6765):821-3. PubMed ID: 13036185 [No Abstract] [Full Text] [Related]
8. [Advantages of a new coumarin derivative]. MAGNANI B G Clin Med; 1951 Feb; 32(2):236-7. PubMed ID: 14823373 [No Abstract] [Full Text] [Related]
9. [Experience with tromexan]. GARCIA TUIRELLA R; BRUERA EF; DE ROSA J Prensa Med Argent; 1952 May; 39(21):1135-42. PubMed ID: 14948838 [No Abstract] [Full Text] [Related]
10. Spectrophotometric determination of Tromexan in plasma and serum. RIEDERS F; GRUBER CM Proc Soc Exp Biol Med; 1951 Aug; 77(4):684-6. PubMed ID: 14891838 [No Abstract] [Full Text] [Related]
12. Tromexan therapy; dosage and indications. HOUGIE C Lancet; 1951 Dec; 2(6694):1118-20. PubMed ID: 14881580 [No Abstract] [Full Text] [Related]
13. Further pharmacologic aspects of tromexan (pelantan or ethyl biscumacetate). GRUBER CM; LEE KS; RIEDERS F Arch Int Pharmacodyn Ther; 1952; 90(4):488-97. PubMed ID: 12986946 [No Abstract] [Full Text] [Related]
14. [A new anticoagulant, tromexan; its action in health and disease and the interference of other medicinals]. AVELLANEDA M; CASTRO CM; STRITZLER G Cardiologia (Basel); 1953; 22(6):321-32. PubMed ID: 13082497 [No Abstract] [Full Text] [Related]
15. Clinical experience with the anticoagulant, tromexan. BRONSTEIN MR; WITKIND E Am J Med Sci; 1951 Dec; 222(6):677-85. PubMed ID: 14885211 [No Abstract] [Full Text] [Related]
16. Ethyl biscoumacetate (tromexan) in human milk. ILLINGWORTH RS; FINCH E J Obstet Gynaecol Br Emp; 1959 Jun; 66():487-8. PubMed ID: 13852719 [No Abstract] [Full Text] [Related]
17. Severe hemorrhage due to tromexan; report of three cases. GRIPE RP N Engl J Med; 1951 Nov; 245(21):803-7. PubMed ID: 14882429 [No Abstract] [Full Text] [Related]
18. [Resorption of arterial embolus by tromexan]. CID DOS SANTOS Mem Acad Chir (Paris); 1952 Apr; 78(12-13):361-2. PubMed ID: 14947580 [No Abstract] [Full Text] [Related]